RAF around the Edges - The Paradox of BRAF Inhibitors

被引：35
|
作者：
Weeraratna, Ashani T. [1 ]
机构：
[1] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2012年 / 366卷 / 03期
关键词：
RESISTANCE; MELANOMA;
D O I：
10.1056/NEJMe1111636
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：271 / 273
页数：3
相关论文
共 50 条
  • [1] Paradox breakers — promising novel RAF inhibitors
    Diana Romero
    Nature Reviews Clinical Oncology, 2016, 13 (1) : 2 - 2
  • [2] MEK and RAF inhibitors for BRAF-mutated cancers
    Belden, Sarah
    Flaherty, Keith T.
    EXPERT REVIEWS IN MOLECULAR MEDICINE, 2012, 14 : e17
  • [3] The "SWOT" of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?
    Nissan, Moriah H.
    Solit, David B.
    CURRENT ONCOLOGY REPORTS, 2011, 13 (06) : 479 - 487
  • [4] The “SWOT” of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?
    Moriah H. Nissan
    David B. Solit
    Current Oncology Reports, 2011, 13 : 479 - 487
  • [5] Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
    Girotti, Maria Romina
    Lopes, Filipa
    Preece, Natasha
    Niculescu-Duvaz, Dan
    Zambon, Alfonso
    Davies, Lawrence
    Whittaker, Steven
    Saturno, Grazia
    Viros, Amaya
    Pedersen, Malin
    Suijkerbuijk, Bart M. J. M.
    Menard, Delphine
    McLeary, Robert
    Johnson, Louise
    Fish, Laura
    Ejiama, Sarah
    Sanchez-Laorden, Berta
    Hohloch, Juliane
    Carragher, Neil
    Macleod, Kenneth
    Ashton, Garry
    Marusiak, Anna A.
    Fusi, Alberto
    Brognard, John
    Frame, Margaret
    Lorigan, Paul
    Marais, Richard
    Springer, Caroline
    CANCER CELL, 2015, 27 (01) : 85 - 96
  • [6] RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    Poulikos I. Poulikakos
    Chao Zhang
    Gideon Bollag
    Kevan M. Shokat
    Neal Rosen
    Nature, 2010, 464 : 427 - 430
  • [7] RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    Poulikakos, Poulikos I.
    Zhang, Chao
    Bollag, Gideon
    Shokat, Kevan M.
    Rosen, Neal
    NATURE, 2010, 464 (7287) : 427 - U126
  • [8] A critical review of RAF inhibitors in BRAF-mutated glioma treatment
    Khoury, John-Victor El
    Wehbe, Sophie
    Attieh, Fouad
    Boutros, Marc
    Kesrouani, Carole
    Kourie, Hampig Raphael
    PHARMACOGENOMICS, 2024, 25 (07) : 343 - 355
  • [9] BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
    Schreck, Karisa C.
    Grossman, Stuart A.
    Pratilas, Christine A.
    CANCERS, 2019, 11 (09)
  • [10] Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors
    Claire V. Chatelle
    Désirée Hövermann
    Anne Müller
    Hanna J. Wagner
    Wilfried Weber
    Gerald Radziwill
    Scientific Reports, 6
12345